BioNexus Gene Lab Corp.
NASDAQ Capital MarketTotal Valuation
BioNexus Gene Lab Corp. carries a market capitalization of 4.59M, placing it among publicly traded companies globally. Its enterprise value stands at 538,961.71, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.59M |
| Enterprise Value | 538,961.71 |
Share Statistics
BioNexus Gene Lab Corp. currently has 2.42M shares outstanding.
| Shares Outstanding | 2.42M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.81, and the price-to-book ratio stands at 0.32.
| PE Ratio | N/A |
| PS Ratio | 0.81 |
| PB Ratio | 0.32 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | -3.78 |
| P/OCF Ratio | -3.69 |
Enterprise Valuation
| EV / Sales | 0.10 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
BioNexus Gene Lab Corp. maintains a current ratio of 6.52, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.67, indicating elevated leverage, while an interest coverage ratio of -166.02 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.52 |
| Quick Ratio | 5.27 |
| Debt / Equity | 2.67 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -166.02 |
Financial Efficiency
| Return on Equity (ROE) | -21.95 |
| Return on Assets (ROA) | -31.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.95 |
Stock Price Statistics
BioNexus Gene Lab Corp.'s stock has declined approximately -30.4878% over the past 52 weeks. The 50-day moving average sits at 2.19, while the 200-day moving average is 3.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | -30.4878% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 3.68 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioNexus Gene Lab Corp. generated 5.31M in revenue and converted that into -2.90M in net income, yielding earnings per share of -1.45. EBITDA reached -2.94M, while operating income came in at -3.11M.
| Revenue | 5.31M |
| Gross Profit | 740,934.00 |
| Operating Income | -3.11M |
| Pretax Income | -2.90M |
| Net Income | -2.90M |
| EBITDA | -2.94M |
| EBIT | -3.11M |
| Earnings Per Share (EPS) | -1.45 |
Balance Sheet
BioNexus Gene Lab Corp. holds 3.96M in cash and equivalents against 216,428.00 in total debt, resulting in a net debt position of -3.96M. Total book value stands at 13.20M, with working capital of 4.40M providing operational flexibility.
| Cash & Cash Equivalents | 3.96M |
| Total Debt | 216,428.00 |
| Net Debt | -3.96M |
| Equity (Book Value) | 13.20M |
| Book Value Per Share | 6.59 |
| Working Capital | 4.40M |
Cash Flow
BioNexus Gene Lab Corp. produced -1.16M in operating cash flow over the past twelve months. After subtracting -28,244.00 in capital expenditures, free cash flow totaled -1.19M - equivalent to -0.59 per share.
| Operating Cash Flow | -1.16M |
| Capital Expenditures | -28,244.00 |
| Free Cash Flow | -1.19M |
| FCF Per Share | -0.59 |
Margins
BioNexus Gene Lab Corp. operates with a gross margin of 13.95, reflecting its pricing power and cost economics. The operating margin of -58.63 and net profit margin of -54.70 provide insight into operational efficiency.
| Gross Margin | 13.95 |
| Operating Margin | -58.63 |
| Pretax Margin | -54.70 |
| Profit Margin | -54.70 |
| EBITDA Margin | -55.39 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.38 |
| FCF Yield | -26.44 |
Stock Splits
BioNexus Gene Lab Corp.'s most recent stock split took place on April 7, 2025 with a 10:1 split ratio.
| Last Split Date | 4/7/2025 |
| Split Ratio | 10:1 |
Scores
BioNexus Gene Lab Corp. posts an Altman Z-Score of 1.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.67 |